Oncology Central

Is there an accurate biomarker test for thyroid cancer recurrence on the horizon?


Patients who are diagnosed with differentiated thyroid cancer (DTC) have favorable survival rates of over 90%; however, up to 30% of them develop recurrent disease leading to considerable morbidity [1]. Multiple prognostic systems have been developed for thyroid cancer, which are effective in predicting mortality, but not as effective in predicting recurrence [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.